1
|
Blázquez-Castro A, Fernández-Piqueras J, Santos J. Genetic Material Manipulation and Modification by Optical Trapping and Nanosurgery-A Perspective. Front Bioeng Biotechnol 2020; 8:580937. [PMID: 33072730 PMCID: PMC7530750 DOI: 10.3389/fbioe.2020.580937] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Accepted: 09/01/2020] [Indexed: 11/13/2022] Open
Abstract
Light can be employed as a tool to alter and manipulate matter in many ways. An example has been the implementation of optical trapping, the so called optical tweezers, in which light can hold and move small objects with 3D control. Of interest for the Life Sciences and Biotechnology is the fact that biological objects in the size range from tens of nanometers to hundreds of microns can be precisely manipulated through this technology. In particular, it has been shown possible to optically trap and move genetic material (DNA and chromatin) using optical tweezers. Also, these biological entities can be severed, rearranged and reconstructed by the combined use of laser scissors and optical tweezers. In this review, the background, current state and future possibilities of optical tweezers and laser scissors to manipulate, rearrange and alter genetic material (DNA, chromatin and chromosomes) will be presented. Sources of undesirable effects by the optical procedure and measures to avoid them will be discussed. In addition, first tentative approaches at cellular-level genetic and organelle surgery, in which genetic material or DNA-carrying organelles are extracted out or introduced into cells, will be presented.
Collapse
Affiliation(s)
- Alfonso Blázquez-Castro
- Department of Biology, Faculty of Sciences, Autonomous University of Madrid, Madrid, Spain.,Genome Dynamics and Function Program, Genome Decoding Unit, Severo Ochoa Molecular Biology Center (CBMSO), CSIC-Autonomous University of Madrid, Madrid, Spain
| | - José Fernández-Piqueras
- Department of Biology, Faculty of Sciences, Autonomous University of Madrid, Madrid, Spain.,Genome Dynamics and Function Program, Genome Decoding Unit, Severo Ochoa Molecular Biology Center (CBMSO), CSIC-Autonomous University of Madrid, Madrid, Spain.,Institute of Health Research Jiménez Diaz Foundation, Madrid, Spain.,Consortium for Biomedical Research in Rare Diseases (CIBERER), Carlos III Institute of Health, Madrid, Spain
| | - Javier Santos
- Department of Biology, Faculty of Sciences, Autonomous University of Madrid, Madrid, Spain.,Genome Dynamics and Function Program, Genome Decoding Unit, Severo Ochoa Molecular Biology Center (CBMSO), CSIC-Autonomous University of Madrid, Madrid, Spain.,Institute of Health Research Jiménez Diaz Foundation, Madrid, Spain.,Consortium for Biomedical Research in Rare Diseases (CIBERER), Carlos III Institute of Health, Madrid, Spain
| |
Collapse
|
2
|
Laoudj-Chenivesse D, Carnac G, Bisbal C, Hugon G, Bouillot S, Desnuelle C, Vassetzky Y, Fernandez A. Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle. J Mol Med (Berl) 2004; 83:216-24. [PMID: 15551024 DOI: 10.1007/s00109-004-0583-7] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2004] [Accepted: 07/14/2004] [Indexed: 12/16/2022]
Abstract
Facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant neuromuscular disorder, has been causally related to deletion of tandemly arrayed 3.3 kb repeats (D4Z4) on chromosome 4q35. Although increased expression of several 4q35 genes has been reported, two recent studies dispute this, finding no significant changes in the transcriptional level of any of the 4q35 genes, among which is the heart and muscle-specific isoform of the adenine nucleotide translocator (ANT1). We found markedly increased levels of ANT1 protein in both unaffected and affected FSHD muscles in comparison to control healthy muscles. Comparative protein expression analysis between healthy, Duchenne muscular dystrophy, and FSHD muscle shows that proteins involved in mitochondrial function and protection from oxidative stress are also reproducibly and specifically modified in all FSHD muscles, including clinically unaffected muscles. Increased ANT1 expression and mitochondrial dysfunction may thus be initial events in FSHD pathogenesis and represent potential therapeutic targets.
Collapse
Affiliation(s)
- Dalila Laoudj-Chenivesse
- Centre de Recherche en Biochimie et Macromoléculaire, FRE-2593-CNRS, 1919 Route de Mende, 34293, Montpellier cedex 5, France.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
Facioscapulohumeral muscular dystrophy (FSHD; MIM 158900), is an autosomal dominant neuromuscular disorder. The disease is characterized by the weakness of the muscles of the face, upper-arm and shoulder girdle. The gene for FSHD has been mapped to 4q35 (FSHD1A) and is closely linked to D4F1O4S1, which detects two highly polymorphic loci (located at 4q35 and 10q26), with restriction enzyme EcoRI. The polymorphic EcoRI fragment detected with D4F1O4S1 is composed almost entirely of D4Z4 (3.3 kb) tandem repeats. In FSHD patients a deletion of the integral number of D4Z4 repeats generates a fragment which is usually smaller than 35 kb, whereas in normal controls, the size usually ranges from 50 to 300 kb. These 'small' EcoRI fragments segregate with FSHD in families but appear as de novo deletions in the majority of sporadic cases. Each 3.3 kb repeat contains two homeobox domains neither of which has yet been proven to encode a protein. D4Z4 is located adjacent to the 4q telomere and cross hybridizes to several different regions of the genome. Although D4Z4 probably does not encode a protein with any direct association to FSHD, a clear correlation has been shown between the deletion size at this locus and the age at onset of the disease in FSHD patients. In approximately 5-10% of FSHD families the disease locus is unlinked to 4q35 (locus designated FSHD1B), however, none of the non 4q35 loci for FSHD have yet been chromosomally located. Thus so far, only one gene, FRG1 (FSHD region gene 1) has been identified from the FSHD candidate region on 4q35. The apparent low level of expressed sequences from within this region, the integral deletions of D4Z4 repeats observed in FSHD patients and the close proximity of these repeats to the 4q telomere, all suggest that the disease may be the result of position effect variegation. To date, the molecular diagnosis of FSHD with D4F104S1 has been most secure in those families which are linked to other 4q35 markers. Recent studies based on the distinction of 4q35 fragments from those from 10q26 will facilitate molecular diagnosis. The pathophysiology and biochemical defect in FSHD still remains to be elucidated. The identification of the FSHD gene and characterization of the gene product will not only potentiate accurate diagnosis but may also unravel the complexities of the 4q35 FSHD region.
Collapse
Affiliation(s)
- J Fisher
- Institute of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff, UK
| | | |
Collapse
|